PTO/SB/64/PCT (7-99)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.			
PETITION FOR REVIVAL OF AN INTERNATIONAL APPLICATION FOR PATENT DESIGNATING THE U.S. ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(b)  Ocket Number (Optional GA0116PCT)			
First named inventor: ROBERTS, Bruce L.	, \ -		
International (PCT) Application No.: PCT/US99/01462 U.S. Application No.: PCT/US99/01462	10.: HC		
Filed: January 25, 1999			
Title: ANTIGEN-SPECIFIC CELLS, METHODS OF GENERATING THESE CELLS AND USES THEREOF	CEIVED		
Attention: PCT Legal Staff	DEC 2000		
Box PCT Assistant Commissioner for Patents Washington, D.C. 20231	Staff stinnal Phric		
The above-identified application became abandoned as to the United States because the fees and documents required by 35 U.S.C. 371(c) were not filed prior to the expiration of the time set in 37 CFR 1.494(b) or (c) or 1.495(b) or (c) (as applicable). The date of abandonment is the day after the date on which the 35 U.S.C. 371(c) requirements were due. See 37 CFR 1.494(h) or 1.495(i).			
APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION			
NOTE: A grantable petition requires the following items:  (1) Petition fee  (2) Proper reply  (3) Terminal disclaimer with disclaimer fee required for all international applications having an international filing date before June 8, 1995; and  (4) Statement that the entire delay was unintentional.			
1. Petition fee  Small entity - fee \$ (37 CFR 1.17(m))  Small entity statement enclosed herewith.  Small entity statement previously filed.  Statement previously filed.  Other than small entity - fee \$_1,210.00 (37 CFR 1.17(m))			
2. Proper reply			
A. The proper reply (the missing 35 U.S.C. 371(c) requirements) in the form of  a continuing application under 35 USC 111(a) and 37 CFR 1.53(b) (identify type of reply):			
has been filed previously on $\overline{X} \ \text{is enclosed herewith.}$			
÷			

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/64/PCT (7-99)

Approved for use through 09/30/2000. OMB 0651-0031

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

3.	Terminal disclaimer with disclaimer fee	
Since this international application has an international filing date on or after June 8, 1995, no terminal disclaimer is required.		
A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$ for a small entity or \$ for other than a small entity) equivalent to the period of abandonment is enclosed herewith (see PTO/SB/63).		
<ol> <li>Statement. The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional.</li> </ol>		
	08 09 /ov	Debouh a Dug Signature
Tele Nun ,	ephone	DUGAN, Deborah A.  Typed or printed name  Genzyme Corporation 15 Pleasant Street Connector, P.O. Box 9322  Address  Framingham, MA 01701-9322 US
End	closures: X Fee Payment	Framingham, MA 01701-9322 00
	X Reply	
	Terminal Disclaimer Form	
	Small Entity Status Form	
	Authorization for Cmmr. to che or credit overpayment to Depo A duplicate copy of this sheet	osit Acct. No. 07-1074.